Deferasirox Structural Formula. (Exjade 01)
Exjade Tablet, For Suspension
Product Images NDC 0078-0470
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Exjade (NDC 0078-0470). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1. Changes In Liver Iron Concentration And Serum Ferritin Following Exjade (5 30 mg/kg Per Day) In Study 1. (Exjade 02)
This appears to be a table or chart displaying information related to liver iron content and serum ferritin levels in relation to dosage of a medication called EXJADE®. The table displays different measurements for liver iron content and serum ferritin before and after treatment with EXJADE® at different dosages (in mg/kg/day). It is not possible to provide a more detailed description without additional context.*
Principal Display Panel – Package Label – 125 mg Tablets (Exjade 03)
Principal Display Panel – Package Label – 250 mg Tablets (Exjade 04)
Principal Display Panel – Package Label – 500 mg Tablets (Exjade 05)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
